Table 2.

Recent Phase II/III RCTs for dcSSc

Therapeutic	Sample Size	Skin Outcome Measure	Result of skin outcome measure
Tocilizumab [21]	N=212	Primary outcome: ΔmRSS at week 48	Least squares mean ΔmRSS −6.1 in tocilizumab arm and −4.4 in placebo arm; P=0.10
Nintedanib [19]	N=576	Secondary outcome: ΔmRSS at week 52	Adjusted mean ΔmRSS −2.17 in the nintedanib arm and −1.96 in the placebo arm; P=0.58
Lenabasum [23]	N=363	Secondary outcome: ΔmRSS at week 52	Mean ΔmRSS −8.1 in the placebo arm and −6.7 in the lenabasum arm
Abatacept [24]	N=88	Primary outcome: ΔmRSS at week 52	Adjusted mean ΔmRSS from baseline −6.24 in abatacept arm and −4.49 in placebo arm; P=0.28
Riociguat [25]	N=109	Primary outcome: ΔmRSS at week 52	Mean ΔmRSS −2.09 for riociguat arm and −0.77 for placebo arm; P=0.08